

September 1, 2017

Corporate Relationship Department
BSE Limited
Dalal Street, Fort
Mumbai – 400 001
Fax Nos.: 022-22723121 / 22723719

National Stock Exchange of India Ltd.
“Exchange Plaza”
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 051
Fax Nos.: 022-26598120/ 26598237

Scrip Code: 500124

Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Intimation

This is to inform you that on 31 August 2017, the United States District Court, for the District of Delaware, issued its judgment in favour of Dr. Reddy's Laboratories Limited, ruling that the proposed generic version of Suboxone (buprenorphine and naloxone) sublingual film does not infringe U.S. Patent Nos. 8,017,150; 8,603,514 and 8,900,497 as asserted by Indivior.

A company spokesperson stated “We are pleased with the verdict passed by the US District Court of Delaware in Dr. Reddy's favour, on the patent litigation of the drug Suboxone. The judgment reiterates our commitment to providing affordable and innovative medicines that address the unmet and under-met needs of patients around the world.”

Suboxone (buprenorphine and naloxone) sublingual film is indicated for the maintenance treatment of opioid dependence. Reckitt Benckiser developed Suboxone sublingual film using MonoSol Rx's PharmFilm technology. In December, 2014, Reckitt Benckiser de-merged its pharmaceuticals business as Indivior. The U.S. Food and Drug Administration (USFDA) has approved Suboxone film in four strengths: 2 mg /0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg (buprenorphine/naloxone).

This is for your information and record.

With regards,



Vikas Sabharwal
Assistant Company Secretary

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY)